Catalyst Wire Dossier Catalyst Wire Dossier

Olopatadine 0.2% Ophthalmic Solution

olopatadine hydrochloride · Alcon
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Olopatadine 0.2% Ophthalmic Solution, covering 2013-07-17 to 2023-08-04. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis [Phase 2]

See pricing